Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.58% is 47% below its 5-year average of -21.53%, near the low end of its 5-year range (-35.24%–-13.79%).
2.23% above its 12-month average of -32.30%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.55%.
RETURN ON ASSETS (ROA)
-31.58%
RETURN ON ASSETS (ROA) AVG TTM
-32.30%
RETURN ON ASSETS (ROA) AVG 3Y
-25.03%
RETURN ON ASSETS (ROA) AVG 5Y
-21.53%
RETURN ON ASSETS (ROA) AVG 10Y
-28.25%
RETURN ON ASSETS (ROA) AVG 15Y
-18.16%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+2.23%
CURRENT VS 3Y AVG
-26.17%
CURRENT VS 5Y AVG
-46.71%
CURRENT VS 10Y AVG
-11.78%
CURRENT VS 15Y AVG
-73.88%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+2.05%
vs the sector median at left
Xenon Pharmaceuticals Inc.
Market Cap
$3.52B
Return on Assets (ROA)
-31.58%
TTM Avg
-32.30%
3Y Avg
-25.03%
5Y Avg
-21.53%
Market Cap
$3.53B
Return on Assets (ROA)
-1.28%
TTM Avg
-8.27%
3Y Avg
-17.73%
5Y Avg
-16.90%
Market Cap
$3.55B
Return on Assets (ROA)
7.70%
TTM Avg
3.29%
3Y Avg
-0.81%
5Y Avg
-2.88%
Market Cap
$3.47B
Return on Assets (ROA)
-27.35%
TTM Avg
-41.78%
3Y Avg
-34.97%
5Y Avg
-41.24%
Market Cap
$3.46B
Return on Assets (ROA)
-13.36%
TTM Avg
-17.34%
3Y Avg
-16.80%
5Y Avg
-15.30%
Market Cap
$3.57B
Return on Assets (ROA)
-11.52%
TTM Avg
-33.33%
3Y Avg
-29.18%
5Y Avg
-25.57%
Market Cap
$3.43B
Return on Assets (ROA)
-69.27%
TTM Avg
-58.09%
3Y Avg
-65.66%
5Y Avg
-83.41%
Market Cap
$3.65B
Return on Assets (ROA)
-62.27%
TTM Avg
-56.63%
3Y Avg
-50.24%
5Y Avg
-125.83%
Market Cap
$3.38B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | $3.52B | -31.58% | -32.30% | -25.03% | -21.53% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | -1.28% | -8.27% | -17.73% | -16.90% |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 7.70% | 3.29% | -0.81% | -2.88% |
| Celcuity Inc. (CELC)vs › | $3.47B | -27.35% | -41.78% | -34.97% | -41.24% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.46B | -13.36% | -17.34% | -16.80% | -15.30% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -11.52% | -33.33% | -29.18% | -25.57% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | -69.27% | -58.09% | -65.66% | -83.41% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.65B | -62.27% | -56.63% | -50.24% | -125.83% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 21.83% | 22.04% | -0.21% | -10.13% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.37B | -180.51% | -129.75% | -129.75% | -129.75% |
ROA
-31.6%
ROE
-32.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.24% |
| 2024-12-31 | -29.36% |
| 2023-12-31 | -18.90% |
| 2022-12-31 | -16.62% |
| 2021-12-31 | -13.79% |
| 2020-12-31 | -15.24% |
| 2019-12-31 | -28.16% |
| 2018-12-31 | -28.18% |
| 2017-12-31 | -66.57% |
| 2016-12-31 | -34.08% |
| 2015-12-31 | -24.63% |
| 2014-12-31 | 14.89% |
| 2013-12-31 | 22.08% |
| 2012-12-31 | -6.79% |
| 2011-12-31 | 0.00% |
